Filing Flows › Tarsus Pharmaceuticals (TARS) › Who owns the stock
Who owns Tarsus Pharmaceuticals (TARS) stock
247 funds reported Tarsus Pharmaceuticals (TARS) shares in their latest 13F filings, worth $3.3B in all. The largest holder is BlackRock ($243M). Last quarter 131 funds added to their stakes and 105 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 3,856,137 | $243M | increase | 2026-06-30 |
| Deep Track Capital, LP | 3,666,768 | $231M | increase | 2026-06-30 |
| RTW Investments, LP | 3,357,059 | $211M | increase | 2026-06-30 |
| Vanguard Group | 2,399,560 | $196M | increase | 2025-12-31 |
| Jupiter Topco LLC | 2,808,796 | $177M | base | 2026-06-30 |
| Paradigm Biocapital Advisors LP | 2,775,649 | $175M | increase | 2026-06-30 |
| Janus Henderson Group | 2,240,963 | $157M | increase | 2026-03-31 |
| Morgan Stanley | 1,827,082 | $115M | decrease | 2026-06-30 |
| Vanguard Capital Management LLC | 1,793,064 | $113M | increase | 2026-06-30 |
| Jennison Associates LLC | 1,663,655 | $105M | decrease | 2026-06-30 |
| Tang Capital Management LLC | 1,568,266 | $98.7M | increase | 2026-06-30 |
| Millennium Management LLC | 1,427,124 | $89.8M | increase | 2026-06-30 |
| Bank of America | 1,193,182 | $75.1M | decrease | 2026-06-30 |
| Geode Capital Management, LLC | 1,105,689 | $69.6M | decrease | 2026-06-30 |
| State Street | 1,072,951 | $67.5M | increase | 2026-06-30 |
Tarsus Pharmaceuticals' latest quarter
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most TARS stock?
By the latest 13F filings: BlackRock ($243M); Deep Track Capital, LP ($231M); RTW Investments, LP ($211M); Vanguard Group ($196M); Jupiter Topco LLC ($177M).
What is the short interest in TARS?
5,731,409 shares were sold short at the 2026-10-15 settlement, -5.59% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.